Bioventus (BVS) Stock Price, News & Analysis

Company Overview

Bioventus Inc. is a medical device and biologics company focused on developing and commercializing products that support bone healing, joint health and surgical recovery. Its portfolio is designed to help healthcare professionals treat musculoskeletal conditions and improve patient outcomes through noninvasive therapies, injectable products and biologic solutions.

The company’s offerings include bone stimulation systems such as EXOGEN, which is used to support fracture healing, as well as injectable osteoarthritis treatments including DUROLANE and GELSYN-3. Bioventus also provides bone graft substitutes and other surgical products, including the OsteoAMP family of biologic solutions, for use in orthopedic and spine procedures.

Bioventus was established as an independent company in 2011 following its separation from Smith & Nephew’s bone healing business. Based in Durham, North Carolina, the company serves healthcare providers and patients in the United States and international markets through direct sales, distributors and other commercial partners.

Key Stats

• Today's Range: $14.23 to $15.10
• 50-Day Range: $12.63 to $15.04
• 52-Week Range: $6.47 to $15.89
• Volume: 592,945 shs
• Average Volume: 391,178 shs
• Market Capitalization: $1.26 billion
• P/E Ratio: 19.53
• Dividend Yield: N/A
• Price Target: $16.80
• Consensus Rating: Buy

Bioventus Stock Analysis - MarketRank™

Bioventus scored higher than 49% of companies evaluated by MarketBeat, and ranked 522nd out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Buy

Consensus Rating

Bioventus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 6 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Bioventus has a consensus price target of $16.80, representing about 11.7% upside from its current price of $15.04.

Amount of Analyst Coverage

Bioventus has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 12.66%

Earnings Growth

Earnings for Bioventus are expected to grow by 12.66% in the coming year, from $0.79 to $0.89 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Bioventus is 18.74, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 35.57.

Price to Earnings Ratio vs. Sector

The P/E ratio of Bioventus is 18.74, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 197.77.

Price to Earnings Growth Ratio

Bioventus has a PEG Ratio of 1.81. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Bioventus has a P/B Ratio of 5.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.65% of the float of Bioventus has been sold short.

Short Interest Ratio / Days to Cover

Bioventus has a short interest ratio ("days to cover") of 6.7.

Change versus previous month

Short interest in Bioventus has recently increased by 7.87%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Bioventus does not currently pay a dividend.

Dividend Growth

Bioventus does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

5 people have searched for BVS on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Bioventus to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Bioventus insiders have not sold or bought any company stock.

Percentage Held by Insiders

33.50% of the stock of Bioventus is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

62.94% of the stock of Bioventus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 10/23/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:BVS
• Previous Symbol: NASDAQ:BVS
• CIK: 1665988
• Web: bioventus.com
• Phone: (919) 474-6700
• Fax: N/A
• Employees: 950
• Year Founded: 2012

Price Target and Rating

• Average Price Target for Bioventus: $16.80
• High Price Target: $19.00
• Low Price Target: $14.00
• Potential Upside/Downside: +11.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.77
• Trailing P/E Ratio: 19.53
• Forward P/E Ratio: 19.04
• P/E Growth: 1.81
• Net Income: $22.73 million
• Net Margins: 9.36%
• Pretax Margin: 6.64%
• Return on Equity: 28.08%
• Return on Assets: 9.82%

Debt

• Debt-to-Equity Ratio: 0.83
• Current Ratio: 1.69
• Quick Ratio: 1.17

Sales & Book Value

• Annual Sales: $581.85 million
• Price / Sales: 2.17
• Cash Flow: $1.35 per share
• Price / Cash Flow: 11.17
• Book Value: $2.76 per share
• Price / Book: 5.45

Miscellaneous

• Outstanding Shares: 84,092,000
• Free Float: 55,921,000
• Market Cap: $1.26 billion
• Optionable: Optionable
• Beta: 0.64